Barbara-Jean Anne Bormann-Kennedy

CIK: 0001635065

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

XERS

Xeris Biopharma Holdings, Inc.

Director

BLRX

BioLineRx Ltd.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

XERS
Xeris Biopharma Holdings, Inc.
Jun 4, 2026
Sale(S)
Direct
16K shares at avg. $6.09$98K
XERS
Xeris Biopharma Holdings, Inc.
Jun 4, 2026
Award(A)
Direct
24.2K shares-
XERS
Xeris Biopharma Holdings, Inc.
Dec 12, 2025
Sale(S)
Direct
15K shares at avg. $7.09$106K
XERS
Xeris Biopharma Holdings, Inc.
Jun 4, 2025
Award(A)
Direct
50K shares-

		Type	Shares	Price		Ownership
Jun 4, 2026	XERS Xeris Biopharma Holdings, Inc.	Sale(S)	16,000	$6.09	$97,507	Direct
Jun 4, 2026	XERS Xeris Biopharma Holdings, Inc.	Award(A)	24,193	-	$0	Direct
Dec 12, 2025	XERS Xeris Biopharma Holdings, Inc.	Sale(S)	15,000	$7.09	$106,415	Direct
Jun 4, 2025	XERS Xeris Biopharma Holdings, Inc.	Award(A)	50,000	-	-	Direct

1-4 of 4 transactions

About BORMANN-KENNEDY BARBARA-JEAN ANNE

BORMANN-KENNEDY BARBARA-JEAN ANNE (SEC CIK 0001635065) files insider reports with the SEC as Director of Xeris Biopharma Holdings, Inc. (XERS) and Director of BioLineRx Ltd. (BLRX).

Signal8 holds 4 ownership filings by BORMANN-KENNEDY BARBARA-JEAN ANNE (1 Form 3, 3 Form 4), filed between Jun 4, 2025 and Jun 5, 2026. Those filings report 4 transactions, from Jun 4, 2025 to Jun 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on BORMANN-KENNEDY BARBARA-JEAN ANNE's filings is in CHICAGO, IL.

Recent filings by BORMANN-KENNEDY BARBARA-JEAN ANNE

Jun 4, 2026: Open-market sale of XERS shares (Form 4, code S).
Jun 4, 2026: Grant or award of XERS shares (Form 4, code A).
Dec 12, 2025: Open-market sale of XERS shares (Form 4, code S).
Jun 4, 2025: Grant or award of XERS shares (Form 4, code A).

Other insiders filing for Xeris Biopharma Holdings, Inc. (XERS)

How to read Form 4 transaction codes